IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Maxwell Life Science IPO is a Book Building listing on BSE SME exchange, with an ipo size of ₹ [●] Cr. The company is based in Mumbai and caters to Pharmaceutical sector. Corporate Professionals Capital is the merchant banker of Maxwell Life Science IPO. It is a SME Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 9th June 2025.
Maxwell Life Science IPO posted revenues of ₹ 127.51 crores and PAT of ₹ 11.35 crores in FY25 on annualised basis.
Revenue:
₹ 127.51 Cr.
EBITDA Margin:
14.61
% 
Net Worth: ₹ 20.14 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Financial results of Maxwell Life Science IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Dec-24 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 78.32 | 60.76 | 56.28 | 38.66 | |
| Net Worth | 20.14 | 11.63 | 6.96 | 6.24 | |
| Total Debt | 20.82 | 19.98 | 15.79 | 15.02 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
95.63
127.51 |
81.72 | 46.67 | 28.53 | |
EBITDA
EBITDA on annualised basis |
13.97
18.63 |
9.35 | 2.83 | 2.30 | |
PAT
PAT on annualised basis |
8.51
11.35 |
4.67 | 0.72 | -0.20 | |
Maxwell Life Science IPO PAT Margin is 8.90 % , ROCE (Return on Capital Employed) is 59.53 % as per latest financial. The below table shows Maxwell Life Science IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Dec-24 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| EBITDA Margin (%) | 14.61 | 11.44 | 6.06 | 8.06 |
| PAT Margin (%) | 8.90 | 5.71 | 1.54 | -0.70 |
| EPS (₹) | 21.89 | 12.00 | 1.84 | -0.51 |
| ROE (%) | 42.25 | 40.15 | 10.34 | -3.21 |
| ROCE (%) | 59.53 | 59.19 | 24.28 | 20.23 |
| ROA (%) | 10.87 | 7.69 | 1.28 | -0.52 |
| Debt to Equity | 1.03 | 1.72 | 2.27 | 2.41 |
The market Capitalisation of Maxwell Life Science IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Maxwell Life Science IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Maxwell Life Science IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Maxwell Life Science IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Maxwell Life Science IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Maxwell Life Science IPO reported revenue of ₹ 127.51 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Maxwell Life Science IPO provide insights into sales growth, market demand, and business scalability.
Maxwell Life Science recorded an EBITDA of ₹ 18.63 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Maxwell Life Science Profit After Tax (PAT) is ₹ 11.35 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 127.51 Cr.
EBITDA Margin:
14.61
%
Net Worth: ₹ 20.14 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Maxwell Life Science operates in Pharmaceutical and Manufacturing Of Pharmaceutical Formulations. The Issue is listed on BSE SME in Jun, 2025. Maxwell Life Science IPO size was with Issue price of .
Merchant Banker(s) of Maxwell Life Science IPO: Corporate Professionals Capital Private Limited
Maxwell Life Science IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Maxwell Life Science IPO listed at a listing price of against the offer price of .
The current market price of Maxwell Life Science is .
Why Us?
